On November 19, 2024, just days after World Diabetes Day, a conference dedicated to new perspectives in the prevention and management of pediatric type 1 diabetes was held in Rome at the Cardinal Colonna Gallery. The event was organized with the unrestricted contribution of leading companies in the field, including Movi, and was attended by experts from institutions and the medical field.

Italy is set to confirm itself as an international leader in the field of diabetes thanks to the recent Law No. 130/2023, the first to introduce national pediatric screening for the early diagnosis of type 1 diabetes and celiac disease. In the words of Hon. Giorgio Mulé, Vice-President of the Chamber of Deputies, this law “represents a solemn commitment to the new generations, ensuring them timely access to early diagnosis of type 1 diabetes and celiac disease. This measure places Italy at the forefront of prevention, promoting a culture of awareness and knowledge of the disease. With such a vision, our country is building an increasingly inclusive community that is attentive to the needs of the youngest age groups.”

During the conference, Enrico Ceribelli, Director of Movi’s Biosystem Business Unit, outlined the company’s commitment to introducing innovative technologies to improve the lives of people with diabetes. He emphasized the importance of ensuring equitable access to advanced solutions that are essential to patients’ quality of life and clinical outcomes. In addition, he highlighted the crucial role of companies in the field in providing not only technological solutions but also highly skilled services, such as technical assistance and training.

Stefano Nervo, president of Diabetes Italia Onlus, was also present at the panel, along with representatives from leading companies and corporations in the field, and emphasized the importance of technological innovation for the management of type 1 diabetes in the pediatric age. He said, “The latest technologies allow continuous monitoring and optimization of therapy, significantly improving the quality of life of patients. It is critical to increase investment in research to ensure access to advanced tools, fostering sustainable disease management that meets the needs of patients and families.”

The conference, sponsored by the Italian Society of Pediatric Endocrinology and Diabetology, the Italian Society of Diabetology, the Association of Diabetes Physicians, the Italian Federation of Pediatric Physicians, the Italian Diabetes Foundation ETS and Diabetes Italia Onlus, reiterated the importance of a multidisciplinary approach. Collaboration between institutions, companies, research centers, pediatricians, and families is crucial to creating an integrated system of pediatric diabetes prevention and care.